Search

Richard Thomas Price Jr.

Examiner (ID: 12400, Phone: (571)272-6892 , Office: P/3643 )

Most Active Art Unit
3643
Art Unit(s)
3643, 3303, 2899, 3616
Total Applications
3843
Issued Applications
3337
Pending Applications
194
Abandoned Applications
336

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 18389891 [patent_doc_number] => 20230158109 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-25 [patent_title] => USE OF CD83 IN COMBINATION THERAPIES [patent_app_type] => utility [patent_app_number] => 17/806302 [patent_app_country] => US [patent_app_date] => 2022-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23361 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17806302 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/806302
USE OF CD83 IN COMBINATION THERAPIES Jun 9, 2022 Abandoned
Array ( [id] => 18005006 [patent_doc_number] => 20220363772 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-17 [patent_title] => METHODS FOR TREATING PROGRESSIVE MULTIPLE SCLEROSIS [patent_app_type] => utility [patent_app_number] => 17/677820 [patent_app_country] => US [patent_app_date] => 2022-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41232 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17677820 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/677820
METHODS FOR TREATING PROGRESSIVE MULTIPLE SCLEROSIS Feb 21, 2022 Abandoned
Array ( [id] => 17672717 [patent_doc_number] => 20220185884 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-16 [patent_title] => ANTI-CD100 ANTIBODIES AND METHODS FOR USING THE SAME [patent_app_type] => utility [patent_app_number] => 17/588427 [patent_app_country] => US [patent_app_date] => 2022-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36439 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17588427 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/588427
Anti-CD100 antibodies and methods for using the same Jan 30, 2022 Issued
Array ( [id] => 17443746 [patent_doc_number] => 20220064251 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-03 [patent_title] => ULTRA-LONG ACTING INSULIN-FC FUSION PROTEINS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/531033 [patent_app_country] => US [patent_app_date] => 2021-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50355 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17531033 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/531033
Cells engineered to express ultra-long acting insulin-Fc fusion proteins Nov 18, 2021 Issued
Array ( [id] => 17368350 [patent_doc_number] => 20220023402 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-27 [patent_title] => IMMUNOMODULATORY PHARMACEUTICAL COMPOSITIONS INCLUDING A SYNTHETIC PEPTIDE AND TRANSFORMING GROWTH FACTOR BETA [patent_app_type] => utility [patent_app_number] => 17/498834 [patent_app_country] => US [patent_app_date] => 2021-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32596 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17498834 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/498834
IMMUNOMODULATORY PHARMACEUTICAL COMPOSITIONS INCLUDING A SYNTHETIC PEPTIDE AND TRANSFORMING GROWTH FACTOR BETA Oct 11, 2021 Abandoned
Array ( [id] => 17355460 [patent_doc_number] => 20220016256 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-20 [patent_title] => METHODS, DEVICE AND REAGENTS TO TREAT ALLERGY AND AUTOIMMUNE DISEASE [patent_app_type] => utility [patent_app_number] => 17/497935 [patent_app_country] => US [patent_app_date] => 2021-10-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13449 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17497935 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/497935
METHODS, DEVICE AND REAGENTS TO TREAT ALLERGY AND AUTOIMMUNE DISEASE Oct 9, 2021 Abandoned
Array ( [id] => 19372913 [patent_doc_number] => 12064452 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-08-20 [patent_title] => Cultured thymus tissue transplantation promotes donor-specific tolerance to allogeneic solid organ transplants [patent_app_type] => utility [patent_app_number] => 17/486045 [patent_app_country] => US [patent_app_date] => 2021-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 85 [patent_no_of_words] => 37154 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 391 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17486045 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/486045
Cultured thymus tissue transplantation promotes donor-specific tolerance to allogeneic solid organ transplants Sep 26, 2021 Issued
Array ( [id] => 17482276 [patent_doc_number] => 20220089780 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-24 [patent_title] => KLOTHO BETA [patent_app_type] => utility [patent_app_number] => 17/411753 [patent_app_country] => US [patent_app_date] => 2021-08-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56949 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17411753 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/411753
KLOTHO BETA Aug 24, 2021 Abandoned
Array ( [id] => 19058989 [patent_doc_number] => 11938183 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-03-26 [patent_title] => Autoimmune antibodies for use in inhibiting cancer cell growth [patent_app_type] => utility [patent_app_number] => 17/366635 [patent_app_country] => US [patent_app_date] => 2021-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 25 [patent_no_of_words] => 12360 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 174 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17366635 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/366635
Autoimmune antibodies for use in inhibiting cancer cell growth Jul 1, 2021 Issued
Array ( [id] => 17140228 [patent_doc_number] => 20210308239 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-07 [patent_title] => THERAPEUTIC INDUCTION OF TOLERANCE USING RECOMBINANT CELL SURFACE ANTIGENS [patent_app_type] => utility [patent_app_number] => 17/345849 [patent_app_country] => US [patent_app_date] => 2021-06-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12471 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17345849 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/345849
THERAPEUTIC INDUCTION OF TOLERANCE USING RECOMBINANT CELL SURFACE ANTIGENS Jun 10, 2021 Abandoned
Array ( [id] => 17227171 [patent_doc_number] => 20210353727 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-18 [patent_title] => IMMUNOMODULATORY THERAPY FOR TYPE 1 DIABETES MELLITUS AUTOIMMUNITY [patent_app_type] => utility [patent_app_number] => 17/336410 [patent_app_country] => US [patent_app_date] => 2021-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6675 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17336410 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/336410
IMMUNOMODULATORY THERAPY FOR TYPE 1 DIABETES MELLITUS AUTOIMMUNITY Jun 1, 2021 Abandoned
Array ( [id] => 17156159 [patent_doc_number] => 20210317210 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-14 [patent_title] => CYTOTOXIC ANTI-LAG-3 MONOCLONAL ANTIBODY AND ITS USE IN THE TREATMENT OR PREVENTION OF ORGAN TRANSPLANT REJECTION AND AUTOIMMUNE DISEASE [patent_app_type] => utility [patent_app_number] => 17/333238 [patent_app_country] => US [patent_app_date] => 2021-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11028 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 104 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17333238 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/333238
CYTOTOXIC ANTI-LAG-3 MONOCLONAL ANTIBODY AND ITS USE IN THE TREATMENT OR PREVENTION OF ORGAN TRANSPLANT REJECTION AND AUTOIMMUNE DISEASE May 27, 2021 Abandoned
Array ( [id] => 18836768 [patent_doc_number] => 11844825 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-12-19 [patent_title] => Method of treating mucopolysaccharidosis type IVA [patent_app_type] => utility [patent_app_number] => 17/314510 [patent_app_country] => US [patent_app_date] => 2021-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 36 [patent_no_of_words] => 13395 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17314510 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/314510
Method of treating mucopolysaccharidosis type IVA May 6, 2021 Issued
Array ( [id] => 17281699 [patent_doc_number] => 11198719 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-12-14 [patent_title] => Ultra-long acting insulin-Fc fusion protein and methods of use [patent_app_type] => utility [patent_app_number] => 17/244097 [patent_app_country] => US [patent_app_date] => 2021-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 12 [patent_no_of_words] => 23187 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17244097 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/244097
Ultra-long acting insulin-Fc fusion protein and methods of use Apr 28, 2021 Issued
Array ( [id] => 17355430 [patent_doc_number] => 20220016226 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-20 [patent_title] => Peptide [patent_app_type] => utility [patent_app_number] => 17/188318 [patent_app_country] => US [patent_app_date] => 2021-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6662 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17188318 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/188318
Peptide Feb 28, 2021 Abandoned
Array ( [id] => 16991855 [patent_doc_number] => 20210230275 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-29 [patent_title] => T CELL REGULATION [patent_app_type] => utility [patent_app_number] => 17/155228 [patent_app_country] => US [patent_app_date] => 2021-01-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17828 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17155228 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/155228
T CELL REGULATION Jan 21, 2021 Abandoned
Array ( [id] => 16976210 [patent_doc_number] => 20210220447 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-22 [patent_title] => METHOD FOR INHIBITING STAT3 ACTIVITY [patent_app_type] => utility [patent_app_number] => 17/154924 [patent_app_country] => US [patent_app_date] => 2021-01-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8002 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17154924 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/154924
Method for inhibiting STAT3 activity comprising administering Ssu72 Jan 20, 2021 Issued
Array ( [id] => 17141697 [patent_doc_number] => 20210309709 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-07 [patent_title] => ULTRA-LONG ACTING INSULIN-FC FUSION PROTEINS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/114395 [patent_app_country] => US [patent_app_date] => 2020-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50325 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17114395 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/114395
Ultra-long acting insulin-Fc fusion proteins Dec 6, 2020 Issued
Array ( [id] => 16598068 [patent_doc_number] => 20210024599 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-28 [patent_title] => MUTANT HSP70i TO PREVENT AUTOIMMUNE DISEASE [patent_app_type] => utility [patent_app_number] => 17/063950 [patent_app_country] => US [patent_app_date] => 2020-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6380 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17063950 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/063950
MUTANT HSP70i TO PREVENT AUTOIMMUNE DISEASE Oct 5, 2020 Abandoned
Array ( [id] => 16948178 [patent_doc_number] => 20210206869 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-08 [patent_title] => METHODS FOR TREATING PROGRESSIVE MULTIPLE SCLEROSIS [patent_app_type] => utility [patent_app_number] => 17/063394 [patent_app_country] => US [patent_app_date] => 2020-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41234 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17063394 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/063394
METHODS FOR TREATING PROGRESSIVE MULTIPLE SCLEROSIS Oct 4, 2020 Abandoned
Menu